Allergan to pay Editas $90m for development of CRISPR eye treatment

20-03-2017

Allergan to pay Editas $90m for development of CRISPR eye treatment

Mark_Kuiken / iStockphoto.com

Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.


Allergan, Editas, agreement, R&D, CRISPR, genome editing, ocular, eye disease, patent, licensing

More on this story

CRISPR specialist raises $80m in funding
28-09-2018

LSIPR